LARIMAR THERAPEUTICS, INC. Earnings Per Share (Diluted)
LARIMAR THERAPEUTICS, INC. (LRMR) reported Earnings Per Share (Diluted) of -$0.61 per share for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2025-11-05
- LARIMAR THERAPEUTICS, INC. earnings per share, diluted for the quarter ending 2025-09-30 was -$0.61.
- LARIMAR THERAPEUTICS, INC. earnings per share, diluted for the quarter ending 2025-06-30 was -$0.41.
- LARIMAR THERAPEUTICS, INC. earnings per share, diluted for the quarter ending 2025-03-31 was -$0.46.
- LARIMAR THERAPEUTICS, INC. earnings per share, diluted for the quarter ending 2024-12-31 was -$0.45.
- LARIMAR THERAPEUTICS, INC. earnings per share, diluted for fiscal 2024 was -$1.32.
- LARIMAR THERAPEUTICS, INC. earnings per share, diluted for fiscal 2023 was -$0.84.
- LARIMAR THERAPEUTICS, INC. earnings per share, diluted for fiscal 2022 was -$1.37.
- LARIMAR THERAPEUTICS, INC. earnings per share, diluted for fiscal 2021 was -$2.95.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 12 month |
|---|---|---|---|---|
| 2025-09-30 | -$0.61 10-Q · filed 2025-11-05 | -$1.04 derived: net income ÷ weighted average shares · filed 2026-08-04 | -$1.50 10-Q · filed 2025-11-05 | -$1.95 derived: net income ÷ weighted average shares · filed 2026-08-04 |
| 2025-06-30 | -$0.41 10-Q · filed 2025-08-14 | -$0.87 10-Q · filed 2025-08-14 | -$1.32 derived: net income ÷ weighted average shares · filed 2026-08-04 | -$1.56 derived: net income ÷ weighted average shares · filed 2026-08-04 |
| 2025-03-31 | -$0.46 10-Q · filed 2025-04-30 | -$0.91 derived: net income ÷ weighted average shares · filed 2026-08-04 | -$1.15 derived: net income ÷ weighted average shares · filed 2026-08-04 | -$1.49 derived: net income ÷ weighted average shares · filed 2026-08-04 |
| 2024-12-31 | -$0.45 derived: net income ÷ weighted average shares · filed 2026-04-20 | -$0.69 derived: net income ÷ weighted average shares · filed 2026-04-20 | -$1.03 derived: net income ÷ weighted average shares · filed 2026-04-20 | -$1.32 10-K · filed 2025-03-24 |
| 2024-09-30 | -$0.24 10-Q · filed 2025-11-05 | -$0.58 derived: net income ÷ weighted average shares · filed 2025-11-05 | -$0.86 10-Q · filed 2025-11-05 | -$1.15 derived: net income ÷ weighted average shares · filed 2026-04-20 |
| 2024-06-30 | -$0.34 10-Q · filed 2025-08-14 | -$0.62 10-Q · filed 2025-08-14 | -$0.92 derived: net income ÷ weighted average shares · filed 2026-04-20 | -$1.14 derived: net income ÷ weighted average shares · filed 2026-04-20 |
| 2024-03-31 | -$0.27 10-Q · filed 2025-04-30 | -$0.57 derived: net income ÷ weighted average shares · filed 2026-04-20 | -$0.78 derived: net income ÷ weighted average shares · filed 2026-04-20 | -$0.97 derived: net income ÷ weighted average shares · filed 2026-04-20 |
| 2023-12-31 | -$0.30 derived: net income ÷ weighted average shares · filed 2026-04-20 | -$0.50 derived: net income ÷ weighted average shares · filed 2026-04-20 | -$0.69 derived: net income ÷ weighted average shares · filed 2026-04-20 | -$0.84 10-K · filed 2025-03-24 |
| 2023-09-30 | -$0.21 10-Q · filed 2024-10-30 | -$0.40 derived: net income ÷ weighted average shares · filed 2024-10-30 | -$0.55 10-Q · filed 2024-10-30 | -$0.76 derived: net income ÷ weighted average shares · filed 2024-10-30 |
| 2023-06-30 | -$0.19 10-Q · filed 2024-08-08 | -$0.34 10-Q · filed 2024-08-08 | -$0.55 derived: net income ÷ weighted average shares · filed 2024-10-30 | -$0.85 derived: net income ÷ weighted average shares · filed 2024-10-30 |
| 2023-03-31 | -$0.15 10-Q · filed 2024-05-09 | -$0.36 derived: net income ÷ weighted average shares · filed 2024-10-30 | -$0.66 derived: net income ÷ weighted average shares · filed 2024-10-30 | -$1.02 derived: net income ÷ weighted average shares · filed 2024-10-30 |
| 2022-12-31 | -$0.21 derived: net income ÷ weighted average shares · filed 2024-03-14 | -$0.54 derived: net income ÷ weighted average shares · filed 2024-03-14 | -$0.94 derived: net income ÷ weighted average shares · filed 2024-03-14 | -$1.37 10-K · filed 2024-03-14 |
| 2022-09-30 | -$0.37 10-Q · filed 2023-11-14 | -$0.84 derived: net income ÷ weighted average shares · filed 2023-11-14 | -$1.32 10-Q · filed 2023-11-14 | -$1.82 derived: net income ÷ weighted average shares · filed 2023-11-14 |
| 2022-06-30 | -$0.47 10-Q · filed 2023-08-10 | -$0.96 10-Q · filed 2023-08-10 | -$1.46 derived: net income ÷ weighted average shares · filed 2023-11-14 | -$2.38 derived: net income ÷ weighted average shares · filed 2023-11-14 |
| 2022-03-31 | -$0.49 10-Q · filed 2023-05-15 | -$0.99 derived: net income ÷ weighted average shares · filed 2023-11-14 | -$1.90 derived: net income ÷ weighted average shares · filed 2023-11-14 | -$2.68 derived: net income ÷ weighted average shares · filed 2023-11-14 |
| 2021-12-31 | -$0.50 derived: net income ÷ weighted average shares · filed 2023-03-14 | -$1.42 derived: net income ÷ weighted average shares · filed 2023-03-14 | -$2.20 derived: net income ÷ weighted average shares · filed 2023-03-14 | -$2.95 10-K · filed 2023-03-14 |
| 2021-09-30 | -$0.92 10-Q · filed 2022-11-10 | -$1.72 derived: net income ÷ weighted average shares · filed 2022-11-10 | -$2.48 10-Q · filed 2022-11-10 | -$3.36 derived: net income ÷ weighted average shares · filed 2022-11-10 |
| 2021-06-30 | -$0.79 10-Q · filed 2022-08-11 | -$1.54 10-Q · filed 2022-08-11 | -$2.43 derived: net income ÷ weighted average shares · filed 2022-11-10 | -$3.07 derived: net income ÷ weighted average shares · filed 2022-11-10 |
| 2021-03-31 | -$0.76 10-Q · filed 2022-05-12 | -$1.64 derived: net income ÷ weighted average shares · filed 2022-11-10 | -$2.29 derived: net income ÷ weighted average shares · filed 2022-11-10 | -$3.34 derived: net income ÷ weighted average shares · filed 2022-11-10 |
| 2020-12-31 | -$0.89 derived: net income ÷ weighted average shares · filed 2022-03-25 | -$1.53 derived: net income ÷ weighted average shares · filed 2022-03-25 | -$2.60 derived: net income ÷ weighted average shares · filed 2022-03-25 | -$3.57 10-K · filed 2022-03-25 |
| 2020-09-30 | -$0.64 10-Q · filed 2021-11-12 | -$1.70 derived: net income ÷ weighted average shares · filed 2021-11-12 | -$2.69 10-Q · filed 2021-11-12 | |
| 2020-06-30 | -$1.21 10-Q · filed 2021-08-12 | -$2.33 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |